Health Condition 1: H401- Open-angle glaucoma
Conditions
Interventions
Intervention1: Amalaki Rasayan: A Sundried Amalaki Churna levigated with freshly prepared Amalaki Swaras in such proportion till Churna get wet and then trituration done. Triturated Amalaki Churna wil
Sponsors
Department of Shalakyatantra Government Ayurved College and Hospital Nagpur
APT Research foundation
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients suffering from symptoms of Primary Open Angle Glaucoma (Adhimantha) and free from any other complications. ( IOP >21 mm Hg, cup: disc ratio (CDR) =0.5 in either eye, difference in CDR >0.2 between the two eyes and/or the presence of glaucomatous features) 2. Patients of age group of 30 to 70 years (Both inclusive). 3. Patients of either gender.
Exclusion criteria
Exclusion criteria: 1.Patients with advanced glaucoma (mean deviation >15 decibels) were excluded, as well as those with evidence of exfoliation, pigment dispersion, or prior filtration surgery. 2. All Primary Closed Angle Glaucoma and secondary Glaucoma. 3. Senile mature or hyper mature cataract. 3. Visual acuity of less than 6/60. 4. Congenital, traumatic, complicated & metabolic cataract or traumatic rise in IOP. 5. Any ocular pathology that can cause diminution of vision and increase in IOP. 6. Patients associated with any systemic illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amalaki Rasayan is effective in preventing the Retinal Ganglionic cell loss in Primary Open Angle Glaucoma Rat model. Timepoint: The drug will be administer for 30 day to rat.There will be 5 groups of rat. Each group will contain 6 animals.The rats will be assessed before and after treatment and retinal ganglion cell count will be taken after treatment. Total duration of the animal trial will be approximately 2 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Participants showing relief from clinical sign and symptoms and improvement in visual acuity. Stopped deterioration of visual field defect. The parameters to be evaluated for secondary outcome are visual field defects on perimetry, Intraocular presssure, Redness of eyes, Headache.Timepoint: The drug willbe given for 60 days. The patients will be assessed before and after treatment. The parameter to assess the secondary outcome will be evaluated after 60th day.Total duration of the study will be 24 months | — |
Countries
India
Contacts
Public ContactDr Hari Narayan Umale
Government Ayurved College and Hospital
Outcome results
None listed